Biomarker & Intervention Discovery

Sarcoidosis

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
Gap size
Primary barrier
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ACE 229CD4 52CYP27B1 19IFNG 31TNF 277
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SALVIANOLIC ACID B ? unclear Mechanistic
CANDOXATRIL ? unclear Mechanistic
CILAZAPRIL inhibits Mechanistic
TP0556351 inhibits Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
SILDENAFIL ? unclear Mechanistic
GEMFIBROZIL ? unclear Mechanistic
RESCINNAMINE ? unclear Mechanistic
SPIRAPRIL ? unclear Mechanistic
INDOMETHACIN ? unclear Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
ARGIPRESSIN ? unclear Mechanistic
METOPROLOL ? unclear Mechanistic
DELAPRIL inhibits Mechanistic
ACETYLCHOLINE ? unclear Mechanistic
THERAPEUTIC GLUCOCORTICOID ? unclear Mechanistic
IMIDAPRIL inhibits Mechanistic
MALATHION inhibits Mechanistic
MOEXIPRIL ? unclear Mechanistic 56.0 nM (IC50)
VORINOSTAT ? unclear Mechanistic
ILEPATRIL inhibits Mechanistic
RXP470.1 inhibits Mechanistic
CGS-27023A ? unclear Mechanistic
NITROPRUSSIDE ? unclear Mechanistic
ENALAPRILAT ANHYDROUS inhibits Mechanistic 1.2 nM (IC50)
TORSEMIDE ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
FOSINOPRIL ? unclear Mechanistic
FUROSEMIDE ? unclear Mechanistic
TEMOCAPRIL HYDROCHLORIDE ? unclear Mechanistic
BENAZEPRIL HYDROCHLORIDE inhibits Mechanistic
CARBARIL inhibits Mechanistic
BUPROPION HYDROCHLORIDE ? unclear Mechanistic
QUINAPRIL ? unclear Mechanistic 8.3 nM (IC50)
COMPOUND 1 [PMID: 24900526] inhibits Mechanistic
COMPOUND 20 [PMID: 22153340] inhibits Mechanistic
BUMETANIDE ? unclear Mechanistic
GALLOPAMIL ? unclear Mechanistic
FLUOXETINE HYDROCHLORIDE ? unclear Mechanistic
AZD6605 inhibits Mechanistic

Showing top 40 of 229 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ANTIVIRAL AGENT ? unclear Mechanistic
IBALIZUMAB ? unclear Mechanistic
CLENOLIXIMAB inhibits Mechanistic
HERBIMYCIN ? unclear Mechanistic
ZANOLIMUMAB ? unclear Mechanistic
CEDELIZUMAB inhibits Mechanistic
VRC-01LS ~ modulates Mechanistic
TREGALIZUMAB activates Mechanistic
PRILIXIMAB ~ modulates Mechanistic
TRX1 ? unclear Mechanistic
ANTISENSE OLIGONUCLEOTIDES ? unclear Mechanistic
TRX-1 inhibits Mechanistic
ANTI-THYMOCYTE GLOBULIN ? unclear Mechanistic
SEMZUVOLIMAB inhibits Mechanistic
KELIXIMAB ~ modulates Mechanistic
ISOCOMPLESTATIN inhibits Mechanistic 130.0 nM (IC50)
CHLOROPEPTIN inhibits Mechanistic 130.0 nM (IC50)
CHEMBL3143464 inhibits Mechanistic 130.0 nM (IC50)
CHEMBL3138360 activates Mechanistic 73000.0 nM (EC50)
CHEMBL3138345 activates Mechanistic 22000.0 nM (EC50)
CHEMBL3138187 activates Mechanistic 4000.0 nM (EC50)
CHEMBL3138374 activates Mechanistic 69600.0 nM (EC50)
CHEMBL3138095 activates Mechanistic 19900.0 nM (EC50)
CHEMBL3138378 activates Mechanistic 70400.0 nM (EC50)
CHEMBL3138119 activates Mechanistic 83800.0 nM (EC50)
CHEMBL231224 inhibits Mechanistic 80000.0 nM (Kd)
CHEMBL267655 inhibits Mechanistic 62000.0 nM (Kd)
CHEMBL388209 inhibits Mechanistic 20000.0 nM (Kd)
CHEMBL230799 inhibits Mechanistic 13000.0 nM (Kd)
CHEMBL267658 inhibits Mechanistic 26000.0 nM (Kd)
CHEMBL388208 inhibits Mechanistic 26000.0 nM (Kd)
CHEMBL267657 inhibits Mechanistic 16000.0 nM (Kd)
CHEMBL230798 inhibits Mechanistic 6000.0 nM (Kd)
CHEMBL388207 inhibits Mechanistic 27000.0 nM (Kd)
CHEMBL230796 inhibits Mechanistic 35000.0 nM (Kd)
CHEMBL1852155 inhibits Mechanistic 210.0 nM (IC50)
CYCLOTRIAZADISULFONAMIDE HYDROCHLORIDE inhibits Mechanistic 330.0 nM (IC50)
CHEMBL4783030 inhibits Mechanistic 2810.0 nM (IC50)
CHEMBL4755141 inhibits Mechanistic 860.0 nM (IC50)
CHEMBL4783761 inhibits Mechanistic 950.0 nM (IC50)

Showing top 40 of 52 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
TENOFOVIR DISOPROXIL FUMARATE ? unclear Mechanistic
CHEMBL:CHEMBL2036072 ? unclear Mechanistic
GAMMA-INTERFERON ? unclear Mechanistic
DEFERASIROX ? unclear Mechanistic
RIFAMPIN ? unclear Mechanistic
TRICHOSTATIN A ? unclear Mechanistic
DECITABINE ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
SOY PROTEIN ISOLATE ? unclear Mechanistic
CTA091 inhibits Mechanistic
CHEMBL389014 inhibits Mechanistic 554.0 nM (IC50)
CHEMBL253613 inhibits Mechanistic 616.0 nM (IC50)
CHEMBL255088 inhibits Mechanistic 554.0 nM (IC50)
CHEMBL1170908 inhibits Mechanistic 616.1 nM (IC50)
CHEMBL4099180 inhibits Mechanistic 60.2 nM (IC50)
CHEMBL4081152 inhibits Mechanistic 95.2 nM (IC50)
CHEMBL4104395 inhibits Mechanistic 570.0 nM (IC50)
CHEMBL4074768 inhibits Mechanistic 410.0 nM (IC50)
KETOCONAZOLE inhibits Mechanistic 340.0 nM (IC50)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
GANCICLOVIR ? unclear Mechanistic
EMAPALUMAB inhibits Mechanistic
PEFLOXACIN ? unclear Mechanistic
TRETINOIN ? unclear Mechanistic
AMITRIPTYLINE HYDROCHLORIDE ? unclear Mechanistic
MELPHALAN ? unclear Mechanistic
CISPLATIN ? unclear Mechanistic
EDRECOLOMAB ? unclear Mechanistic
METHYLPREDNISOLONE ? unclear Mechanistic
DOXIFLURIDINE ? unclear Mechanistic
CYCLOPHOSPHAMIDE ANHYDROUS ? unclear Mechanistic
URSODIOL ? unclear Mechanistic
PREDNISONE ? unclear Mechanistic
BLEOMYCIN ? unclear Mechanistic
AMIKACIN ? unclear Mechanistic
THERAPEUTIC GLUCOCORTICOID ? unclear Mechanistic
FONTOLIZUMAB inhibits Mechanistic
AMG-811 inhibits Mechanistic
THEOPHYLLINE ? unclear Mechanistic
PENICILLIN G POTASSIUM ? unclear Mechanistic
TRASTUZUMAB ? unclear Mechanistic
FUMARIC ACID ? unclear Mechanistic
SURAMIN ? unclear Mechanistic
IBUPROFEN, SODIUM SALT ? unclear Mechanistic
THERAPEUTIC MELATONIN ? unclear Mechanistic
THERAPEUTIC AUTOLOGOUS LYMPHOCYTES ? unclear Mechanistic
THROMBIN ALFA ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
RECOMBINANT INTERLEUKIN-1-BETA ? unclear Mechanistic
CHEMBL3288259 inhibits Mechanistic 10000.0 nM (Kd)
CHEMBL3288260 inhibits Mechanistic 7000.0 nM (Kd)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NERELIMOMAB inhibits Mechanistic
CROMOLYN SODIUM ? unclear Mechanistic
PLACULUMAB inhibits Mechanistic
METHYLENE BLUE ? unclear Mechanistic
ALTEPLASE ? unclear Mechanistic
CARBOPLATIN ? unclear Mechanistic
GENTAMICIN ? unclear Mechanistic
GOLIMUMAB inhibits Mechanistic
BUPIVACAINE ? unclear Mechanistic
PENTOXIFYLLINE ? unclear Mechanistic 85000.0 nM (IC50)
BENZO[E]PYRENE ? unclear Mechanistic
THALIDOMIDE ? unclear Mechanistic
PYRAZINAMIDE ? unclear Mechanistic
GLIMEPIRIDE ? unclear Mechanistic
OMEPRAZOLE ? unclear Mechanistic
LENERCEPT inhibits Mechanistic
ADALIMUMAB inhibits Mechanistic
PRAZOSIN HYDROCHLORIDE ? unclear Mechanistic
REMTOLUMAB ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
LENABASUM ? unclear Mechanistic
MAGNESIUM SULFATE ANHYDROUS ? unclear Mechanistic
PICIBANIL ? unclear Mechanistic
FLUOCINOLONE ACETONIDE ? unclear Mechanistic
MILTEFOSINE ? unclear Mechanistic
HOMIDIUM BROMIDE ? unclear Mechanistic
OZORALIZUMAB inhibits Mechanistic
PEGSUNERCEPT inhibits Mechanistic
CERTOLIZUMAB PEGOL inhibits Mechanistic
THERAPEUTIC HORMONE ? unclear Mechanistic
NAFAMOSTAT ? unclear Mechanistic
FOLIC ACID ? unclear Mechanistic
ABBV-257 ? unclear Mechanistic
RISPERIDONE ? unclear Mechanistic
COVA322 ? unclear Mechanistic
HYDROXYCHLOROQUINE ? unclear Mechanistic
CERTOLIZUMAB ? unclear Mechanistic
AN0128 ? unclear Mechanistic
5,7-DIHYDROXY-4-METHYLCOUMARIN ? unclear Mechanistic
SORAFENIB ? unclear Mechanistic

Showing top 40 of 277 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.

NCT03593759 Phase: PHASE3 Started: 2019-01-15

Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low do...

NCT01477359 Phase: N/A Started: 2012-08

Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations...

NCT00001532 Phase: N/A Started: 1996-09-13

This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible fo...

NCT00470327 Phase: N/A Started: 2005-09

We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of thes...

NCT07077304 Phase: N/A Started: 2025-11-19

Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of the heart. ICARDs are associated with increased cardiovascular morbidity ...

NCT05415137 Phase: PHASE3 Started: 2022-09-15

This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving sta...

NCT02656381 Phase: N/A Started: 2016-07-26

Background: Uveitis is a serious eye disease that can cause vision loss. Treatment sometimes causes serious side effects or does not work. Researchers want to learn more about uveitis and why some people develop it. Objective: To learn clinical and genetic factors that may make people develop uve...

NCT05890729 Phase: PHASE1, PHASE2 Started: 2023-11-10

A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis

NCT05499637 Phase: PHASE2 Started: 2023-01-17

Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and th...

NCT05819385 Phase: N/A Started: 2025-06-18

This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as well as the possible impacts of these factors on the outcome of progress...

NCT06220526 Phase: NA Started: 2023-08-18

This randomized pilot clinical trial aims to examine whether sample collection with Franseen-type needles are effective for the diagnosis of sarcoidosis, as defined by improved sample quality for pathological diagnosis compared to the conventional Menghini-type needle.

NCT03584022 Phase: NA Started: 2018-11-09

This is safety study. Subjects will be undergoing the surgical procedure of nerve biopsy. After routine surgery without grafting, patients develop swelling, redness, tenderness and dysesthesia at the biopsy site. In order to determine whether grafting is safe compared to not repairing the nerve, it ...

NCT03049254 Phase: N/A Started: 2018-02-09

Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease pro...

NCT05689879 Phase: PHASE3 Started: 2023-03-23

In severe refractory sarcoidosis not responding to conventional immunosuppressive treatment, the third-line tumor necrosis factor (TNF)-alpha inhibitor infliximab is an alternative. Treatment duration is not known, although it has been suggested that relapse rates after withdrawal could be high. We ...

NCT07073963 Phase: NA Started: 2026-02-26

This research study is testing whether Mindfulness-Based Stress Reduction (MBSR) can help reduce fatigue in people with sarcoidosis. The study will also look at whether MBSR can improve symptoms of anxiety and depression. Participants will be placed into one of two groups: * One group will take pa...


Agents Found By Disease-Level Search

Searched directly from “Sarcoidosis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 5-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.